Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

Iron Deficiency Anemia Clinical Trial

Official title:

A Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04268849
• Other study ID #: BariatricsProtocol100719
• Status: Recruiting
• Phase: Phase 3
• Start date: February 27, 2020
• Est. completion date: February 2024

Study information

• Verified date: June 2023
• Source: Auerbach Hematology Oncology Associates P C
• Contact: Michael Auerbach, MD
• Phone: 4107804050
• Email: mauerbachmd[@]abhemonc.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Given the limited long-term effectiveness of traditional weight loss methods, bariatric surgery is increasingly becoming the preferred option for sustained weight loss. With the ascendancy of the laparoscopic approach, the two most common procedures are the Roux-en-Y gastric bypass (RYGB) and the vertical sleeve gastrectomy (VSG).

Because bariatric surgery decreases nutrient intake through restriction, malabsorption, or both, and given that obese patients are often malnourished even before surgery, postoperative micronutrient deficiency, particularly of iron, can be a serious complication and difficult to treat. Iron deficiency anemia has been reported to be as high as 49% in the post-bariatric surgical patient.

The current standard for correcting iron deficiency anemia in the post-operative bariatric surgical patient is oral iron supplements. However, oral iron therapy is known for its caustic effects on the gastric mucosa causing gastric irritation, nausea, epigastric discomfort and constipation. These debilitating symptoms lead to poor adherence and lower long and short-term efficacy. Furthermore, iron absorption from oral iron supplements when taken with food in patients with low iron stores ranges from 2 to 13% and without food 5 to 28%. An alternative and more effective method of iron replenishment is the use of intravenous iron. A litany of published trials, without contradiction, show marked superiority of intravenous iron in improving hemoglobin concentrations and iron parameters when compared to historical controls. Nonetheless, the current recommendations of the American Society of Metabolic and Bariatric Surgery nutritional guidelines, state that oral iron supplementation for IDA is the recommended first line of treatment. Studies are lacking that compare the efficacy of oral versus intravenous (IV) iron therapy for the treatment of IDA in the post-bariatric surgical patient.

The aim of our study is to compare two accepted treatments for iron deficiency anemia (oral ferrous sulfate and intravenous ferumoxytol) for efficacy and speed of response in the treatment of IDA in the post-operative bariatric surgical patient. In this study, 104 bariatric surgical post-operative patients will be randomly assigned 52 each to oral or 52 to a single dose IV iron treatment using double-blind procedures.

The primary outcome will be determined at 6 weeks of treatment with a follow-up at 12 months after treatment. Non-responders at 6 weeks after treatment may, if they qualify (based on inclusion/exclusion criteria), have an open-label IV iron treatment and will be followed with the same evaluations used after the first IV iron treatments.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 104
• Est. completion date: February 2024
• Est. primary completion date: November 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

1. Aged = 18 years

2. Patients who have undergone a Roux-en Y Gastric Bypass or Vertical Sleeve Gastrectomy and are at least 3 months or more out from surgery.

3. Iron deficiency anemia defined as iron deficient with either ferritin<30 mcg/l, TSAT<20%, or anemia with Hgb<13 g/dL for both males and females.

4. Willingness to participate and signing the informed consent form.

Exclusion criteria:

1. Iron overload or disturbances in utilization of iron (e.g. hemochromatosis and hemosiderosis)

2. Decompensated liver cirrhosis or active hepatitis (ALAT > 3 times upper limit of normal)

3. Serum ferritin > 400 ng/mL or transferrin saturation >40 %

4. Active acute or chronic infections (assessed by clinical judgment that may be indicated by White Blood Cells (WBC) and C-Reactive Protein (CRP) when these are available)

5. Rheumatoid arthritis with symptoms or signs of active inflammation

6. Pregnant and nursing women

7. History of multiple allergies (two or more)

8. Known hypersensitivity to ferumoxytol or oral iron or any excipients in the drug products

9. Previous IV iron treatment for IDA

10. Other iron treatment or blood transfusion within 4 weeks prior to the screening or treatment visit

11. Planned elective surgery during the study

12. Any other medical condition that, in the opinion of Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study, e.g. a malignancy, uncontrolled hypertension, unstable ischemic heart disease, or uncontrolled diabetes mellitus

Related Conditions & MeSH terms

• Anemia
• Anemia, Iron-Deficiency
• Deficiency Diseases
• Iron Deficiency Anemia

Intervention

Drug:
• Ferumoxytol
Ferumoxytol (30 mg/mL) intravenous injection in single use vials.
• Saline
Placebo for Ferumoxytol
• Ferrous sulfate tablets
ferrous sulfate tablets containing 60 mg elemental iron
• Vitamin C
Placebo: Vitamin C, 250 mg, given in the same bottle as the oral iron

Locations

Country	Name	City	State
United States	Auerbach Hematology and Oncology	Baltimore	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
Auerbach Hematology Oncology Associates P C	AMAG Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Clinical Global Impression - improvement scale (CGI-2) score at 6 weeks after treatment begins.	The CGI-2 is a measure of treatment response and the efficacy of the treatment based on a 1 to 7 scale where 1 is "very much better" and 7 "very much worse"	6 weeks
Primary	Change in hemoglobin concentration		6 weeks
Secondary	Change in ferritin > 20%		6 weeks
Secondary	Change in Transferrin saturation (TSAT) >19%		6 weeks
Secondary	Quality of Life by visual linear analog scale (LASA)		6 weeks